Haemonetics Corporation
Moat Score — Haemonetics Corporation
Total Moat Score
17 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Haemonetics' TEG hemostasis analyzer platform and its self-described global leadership in advanced viscoelastic testing, built on years of clinical validation and regulatory clearances, represent a durable, hard-to-replicate intangible asset in a genuinely specialized diagnostic niche. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 2 / 5 | Haemonetics competes with scale players like Fresenius and Terumo BCT on manufacturing and distribution; it has no clear low-cost position, and emerging Chinese plasma device makers like Nigale and Haier could eventually compete on price in that geography. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | Once a hospital or plasma collector has standardized on NexSys devices or TEG hemostasis testing, Haemonetics retains real pricing power on the recurring disposables and software that follow the initial device placement. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 1 / 5 | Haemonetics' software, such as NexLynk DMS, gains some value as more donor centers and data accumulate on the platform, but this is a modest effect compared to consumer-facing network businesses and does not meaningfully compound across unrelated customers. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 4 / 5 | Replacing an installed base of NexSys plasmapheresis devices, TEG hemostasis analyzers, or NexLynk donor-management software means requalifying clinical protocols, retraining staff, and re-validating regulatory processes — a genuinely high-friction switch that CSL's own years-long transition away from exclusivity illustrates. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | The global plasma and blood-collection device market supports only a small number of credible suppliers (Haemonetics, Fresenius, Terumo BCT), reflecting real regulatory and capital barriers that limit how many players the market can efficiently support. |